Results 31 to 40 of about 25,762 (279)

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. [PDF]

Kidney International, 2020
E. Rondeau, M. Scully, G. Ariceta, T. Barbour, S. Cataland, N. Heyne, Y. Miyakawa, S. Ortiz, E. Swenson, M. Vallée, S. Yoon, D. Kavanagh, H. Haller, S. Babu, N. Broeders, N. Lietar, Fiona C. Brown, P. Campbell, P. Chowdhury, T. Kasimatis, L. Cirami, L. Caroti, Guilia Antognoli, Yahsou Delmas, V. Dobronravov, Anja Gaeckler, C. Garrouste, G. Greenwood, S. Griffin, Chiu-Ching Huang, I. Chen, Susan Huang, Jin Seok Kim, G. La Manna, G. Comai, M. Cappuccilli, M. Le Quintrec, Guillaume Jeantet, Iino Fumie, Y. Luque, J. Menne, J. Morelle, É. Goffin, Anja Muhlfeld, S. Nagaraj, G. Arepally, D. Oh, M. Okumi, Manuel Praga Terente, E. Gutiérrez, P. Rodríguez, F. Provôt, U. Schönermarck, M. Fischereder, N. Terrada, B. Seitz-Polski, G. Favre, Sonia Boyer-Suavet, M. Vinogradova, T. Kirsanova, E. Wong   +60 more
semanticscholar   +2 more sources

Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports

Journal of Medical Case Reports, 2021
Background Atypical hemolytic uremic syndrome is an exceedingly rare thrombotic microangiopathy caused by accelerated activation of the alternative complement pathway.
Christine J. Kurian, Zachary French, Patrick Kukulich, Matthew Lankiewicz, Sushil Ghimire, Omar H. Maarouf, Sanaa Rizk, Ruben Rhoades   +7 more
doaj   +1 more source

Atypical Hemolytic Uremic Syndrome [PDF]

Seminars in Nephrology, 2013
Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement overactivation. Inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described.
Kavanagh D, Goodship TH, Richards A
openaire   +3 more sources

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Journal of Multidisciplinary Healthcare, 2023
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the triad of hemolytic anemia, thrombocytopenia, and acute kidney injury.
Keval Yerigeri, S. Kadatane, Kai Mongan, Olivia Boyer, Linda Burke, S. Sethi, Christoph Licht, R. Raina   +7 more
semanticscholar   +1 more source

CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome

Frontiers in Immunology, 2023
Introduction Atypical hemolytic uremic syndrome (aHUS) is a rare disease that manifests with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, and is associated with dysregulation of the alternative complement pathway.
R. Piras, E. Valoti, M. Alberti, E. Bresin, C. Mele, M. Breno, L. Liguori, R. Donadelli, M. Rigoldi, A. Benigni, G. Remuzzi, M. Noris   +11 more
semanticscholar   +1 more source

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Journal of Comparative Effectiveness Research, 2023
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated
Teri J Mauch, Michael R. Chladek, S. Cataland, Shruti Chaturvedi, B. Dixon, Katherine Garlo, C. Gasteyger, A. Java, Jorge P. Leguizamo, L. Lloyd-Price, T. Pham, T. Symonds, I. Tomazos, Yan Wang   +13 more
semanticscholar   +1 more source

Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults

Frontiers in Medicine, 2023
Background Despite significant advances in therapeutic management of atypical hemolytic uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on management recommendations remains a topic of ongoing discussion.
Ana Ávila, M. Cao, Mario Espinosa, Joaquín Manrique, Enrique Morales   +4 more
semanticscholar   +1 more source

Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future

Pediatric Drugs, 2023
Atypical hemolytic uremic syndrome is a thrombotic microangiopathy characterized by hemolysis, thrombocytopenia, and acute kidney injury, usually caused by alternative complement system overactivation due to pathogenic genetic variants or antibodies to ...
Evgenia Gurevich, D. Landau
semanticscholar   +1 more source

Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome

Brazilian Journal of Nephrology, 2020
Primary atypical hemolytic-uremic syndrome is a rare disease characterized by non-immune microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction; it is related to alterations in the regulation of the alternative pathway of complement ...
Diana Carolina Bello-Marquez, John Fredy Nieto-Rios, Lina Maria Serna-Higuita, Alfonso Jose Gonzalez-Vergara   +3 more
doaj   +2 more sources

Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in a renal transplant recipient case report

Brazilian Journal of Nephrology, 2020
Thrombotic microangiopathies are disorders characterized by nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and multi-systemic failure.
John Fredy Nieto-Rios, Monica Zuluaga-Quintero, Julio Cesar Valencia-Maturana, Diana Carolina Bello-Marquez, Arbey Aristizabal-Alzate, Gustavo Adolfo Zuluaga-Valencia, Lina Maria Serna-Higuita, Luis Fernando Arias   +7 more
doaj   +2 more sources